<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">565</article-id><article-id pub-id-type="doi">10.25692/ACEN.2018.5.10</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Modeling of age-dependent disorders: relationship between the nervous and endocrine systems</article-title><trans-title-group xml:lang="ru"><trans-title>Моделирование возраст-зависимых заболеваний: связь нервной и эндокринной систем</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stavrovskaya</surname><given-names>Alla V.</given-names></name><name xml:lang="ru"><surname>Ставровская</surname><given-names>Алла Вадимовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Voronkov</surname><given-names>Dmitriy N.</given-names></name><name xml:lang="ru"><surname>Воронков</surname><given-names>Дмитрий Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shestakova</surname><given-names>Ekaterina A.</given-names></name><name xml:lang="ru"><surname>Шестакова</surname><given-names>Екатерина Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ol’shansky</surname><given-names>Artyem S.</given-names></name><name xml:lang="ru"><surname>Ольшанский</surname><given-names>Артем Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yamshchikova</surname><given-names>Nina G.</given-names></name><name xml:lang="ru"><surname>Ямщикова</surname><given-names>Нина Гавриловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gushchina</surname><given-names>Anastasia S.</given-names></name><name xml:lang="ru"><surname>Гущина</surname><given-names>Анастасия Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Illarioshkin</surname><given-names>Sergey N.</given-names></name><name xml:lang="ru"><surname>Иллариошкин</surname><given-names>Сергей Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Center of Neurology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр неврологии»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Medical Research Center of Endocrinology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-12-26" publication-format="electronic"><day>26</day><month>12</month><year>2018</year></pub-date><volume>12</volume><issue>5S</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>79</fpage><lpage>86</lpage><history><date date-type="received" iso-8601-date="2018-12-26"><day>26</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Stavrovskaya A.V., Voronkov D.N., Shestakova E.A., Ol’shansky A.S., Yamshchikova N.G., Gushchina A.S., Illarioshkin S.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, Stavrovskaya A.V., Voronkov D.N., Shestakova E.A., Ol’shansky A.S., Yamshchikova N.G., Gushchina A.S., Illarioshkin S.N.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Stavrovskaya A.V., Voronkov D.N., Shestakova E.A., Ol’shansky A.S., Yamshchikova N.G., Gushchina A.S., Illarioshkin S.N.</copyright-holder><copyright-holder xml:lang="ru">Stavrovskaya A.V., Voronkov D.N., Shestakova E.A., Ol’shansky A.S., Yamshchikova N.G., Gushchina A.S., Illarioshkin S.N.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/565">https://annaly-nevrologii.com/pathID/article/view/565</self-uri><abstract xml:lang="en"><p>Age-dependent disorders are a challenging problem of modern society. Among the most significant age-dependent disorders are Alzheimer's disease (AD), diabetes, metabolic syndrome, etc.; these conditions may be associated to each other and have, at least in part, an interconnecting character. An experimental model of AD induced by intracerebroventricular administration of streptozocin (STZ) mimics some key characteristics of sporadic AD, altering insulin metabolism. The aim of this work was to study glucose metabolism in rats at different periods after intracerebroventricular injection of STZ. To obtain an AD model, STZ in a 0.9% NaCl solution at a dose of 3 mg/kg in 10 μl was administered bilaterally in the brain lateral ventricles on stereotaxic operations. Two and seven weeks after the administration, the weight of the animals was determined, and the glucose levels in tail vein whole blood after intraperitoneal glucose administration at a dose of 1.5 g/kg was measured. A standard glucose tolerance test was performed, and hyperglycemic and postglycemic ratios were calculated. As a result, an impairment of glucose metabolism in rats 7 weeks after intracerebroventricular application of STZ was detected for the first time. Close connection of Alzheimertype neurodegenerative changes and glucose metabolism revealed on this model allows using it for deeper assessment of relationships between the nervous and endocrine systems, including translational studies of novel therapeutic strategies.</p></abstract><trans-abstract xml:lang="ru"><p>Возраст-зависимые заболевания – острейшая проблема современного общества. К числу наиболее значимых возраст-зависимых заболеваний относятся болезнь Альцгеймера (БА), сахарный диабет, метаболический синдром и др., причем эти состояния могут сочетаться и иметь, по крайней мере частично, взаимообусловленный характер. Экспериментальная модель БА, индуцированная внутрижелудочковым введением стрептозоцина, воспроизводит ряд ключевых характеристик спорадической формы БА, нарушая метаболизм инсулина. Целью работы явилось изучение углеводного обмена у крыс на разных сроках после внутрижелудочкового введения стрептозоцина. Для получения модели БА крысам билатерально во время стереотаксических операций вводили стрептозоцин в 0,9% растворе NaCl в дозе 3 мг/кг в 10 мкл в боковые желудочки мозга. Через 2 и 7 недель после введение определяли вес животных, а также уровни глюкозы в цельной крови в хвостовой вене крыс после внутрибрюшинного введения глюкозы в дозе 1,5 г/кг. Выполнялся стандартный глюкозотолерантный тест, а также рассчитывались гипергликемический и постгликемический коэффициенты. В результате впервые было обнаружено нарушение углеводного обмена у крыс через 7 недель после внутрижелудочкового введения STZ. Выявленная на данной модели тесная связь между нейродегенеративными изменениями альцгеймеровского типа и углеводным обменом позволяет использовать ее для более глубокой оценки взаимоотношений нервной и эндокринной система, в том числе в трансляционных исследованиях новых терапевтический стратегий.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Alzheimer's disease</kwd><kwd>streptozocin</kwd><kwd>neurodegeneration</kwd><kwd>glucose metabolism</kwd><kwd>glucose tolerance test</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>болезнь Альцгеймера</kwd><kwd>стрептозоцин</kwd><kwd>нейродегенерация</kwd><kwd>углеводный обмен</kwd><kwd>глюкозотолерантный тест</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Chen Y., Liang Z., Blanchard J. et al. A non-transgenic mouse model (icv-STZ mouse) of Alzheimer’s disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol 2013; 47(2): 711-725. DOI: 10.1007/s12035-012-8375-5. PMID: 23150171.</mixed-citation><mixed-citation xml:lang="ru">Chen Y., Liang Z., Blanchard J. et al. A non-transgenic mouse model (icv-STZ mouse) of Alzheimer’s disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol 2013; 47(2): 711-725. DOI:10.1007/s12035-012-8375-5. PMID: 23150171.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Hoyer S., Lee S.K., Löffler T., Schliebs R. Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann N YAcad Sci 2000; 920: 256–258. DOI: 10.1111/j.1749-6632.2000.tb06932.x. PMID: 11193160.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Hau J. Animal models of human diseases. In: Conn PM (ed) An overview. (in:) Sourcebook of Models for Biomedical Research, Humana Press, Totowa, 2008; 1: 15–20. DOI: org/10.1007/978-1-59745-285-4_1.</mixed-citation></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Iqbal K., Bolognin S., Wang X. et al. Animal models of the sporadic form of Alzheimer’s disease: Focus on the disease and not just the lesions. J Alzheimers Dis 2013; 37: 469–474. DOI: 10.3233/JAD-130827. PMID: 23948903.</mixed-citation><mixed-citation xml:lang="ru">Iqbal K., Bolognin S., Wang X. et al. Animal models of the sporadic form of Alzheimer’s disease: Focus on the disease and not just the lesions. J Alzheimers Dis 2013; 37: 469–474. DOI: 10.3233/JAD-130827. PMID: 23948903.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>Shineman D.W., Basi G.S., Bizon J.L. et al Accelerating drug discovery for Alzheimer’s disease: best practices for preclinical animal studies. Alzheimers Res Ther 2011; 3: 28. DOI: 10.1186/alzrt90. PMID:21943025.</mixed-citation></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Ganda O.P., Rossini A.A., Like A.A. Studies on streptozotocin diabetes. Dia-betes 1976; 25: 595–603. DOI: 10.2337/diab.25.7.595. PMID:132382.</mixed-citation><mixed-citation xml:lang="ru">Ganda O.P., Rossini A.A., Like A.A. Studies on streptozotocin diabetes. Diabetes 1976; 25: 595–603. DOI: 10.2337/diab.25.7.595. PMID:132382.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Degenhardt T.P., Alderson N.L., Arrington D.D. et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocindiabetic rat. Kidney Int2002; 61: 939–950 DOI: 10.1046/j.1523-1755.2002.00207.x. PMID: 11849448.</mixed-citation><mixed-citation xml:lang="ru">Degenhardt T.P., Alderson N.L., Arrington D.D. et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocindiabetic rat. Kidney Int 2002; 61: 939–950 DOI: 10.1046/j.1523-1755.2002.00207.x. PMID: 11849448.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Srinivasan K., Viswanad B., Asrat L. et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and phar-macological screening. Pharmacol Res 2005; 52: 313–320. DOI: 10.1016/j.phrs.2005.05.004. PMID: 15979893.</mixed-citation><mixed-citation xml:lang="ru">Srinivasan K., Viswanad B., Asrat L. et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005; 52: 313–320. DOI: 10.1016/j. phrs.2005.05.004. PMID: 15979893.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Reaven G.M. Banting lecture 1988. Role of insulin resistance in human dis-ease. Diabetes 1988; 37(12): 1595–1607. DOI: 10.1016/0899-9007(97)90878-9. PMID: 3056758.</mixed-citation><mixed-citation xml:lang="ru">Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595–1607. DOI: 10.1016/0899-9007(97)90878-9. PMID: 3056758.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><mixed-citation>Grundy S.M. Metabolic Syndrome update. Trends Cardiovasc Med 2016; 26: 364–373 DOI: 10.1016/j.tcm.2015.10.004. PMID: 26654259.</mixed-citation></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Tanashyan M.M., Lagoda O.V., Antonova K.V. [Chronic cerebrovascular diseases in metabolic syndrome: new approaches to the treatment]. Zhurnal nev-rologii i psikhiatrii im. S.S. Korsakova 2012; 112(11): 21-26 (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Танашян М.М., Лагода О.В., Антонова К.В. Хронические цереброваскулярные заболевания на фоне метаболического синдрома: новые подходы к лечению. Журнал неврологии и психиатрии им. С.С. Корсакова 2012; 112(11): 21-26.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">. Du L.L., Chai D.M., Zhao L.N. et al. AMPK activation ameliorates Alzhei-mer’s disease-like pathology and spatial memory impairment in a streptozotocin induced Alzheimer’s disease model in rats. J Alzheimers Dis 2015; 43(3): 775-784. DOI: 10.3233/JAD-140564. PMID: 25114075.</mixed-citation><mixed-citation xml:lang="ru">Du L.L., Chai D.M., Zhao L.N. et al. AMPK activation ameliorates Alzheimer’s disease-like pathology and spatial memory impairment in a streptozotocin induced Alzheimer’s disease model in rats. J Alzheimers Dis 2015; 43(3): 775-784. DOI: 10.3233/JAD-140564. PMID: 25114075.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Yang W., Ma J., Liu Z. et al. Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induced dementia model of rats. Neurol Sci2014; 35(5): 741-751. DOI: 10.1007/s10072-013-1594-3. PMID: 24337945.</mixed-citation><mixed-citation xml:lang="ru">Yang W., Ma J., Liu Z. et al. Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induced dementia model of rats. Neurol Sci 2014; 35(5): 741-751. DOI: 10.1007/s10072-013-1594-3. PMID: 24337945.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Prakash A., Kalra J.K., Kumar A. Neuroprotective effect of N-acetyl cys-teine against streptozotocin-induced memory dysfunction and oxidative dam-age in rats. J Basic Clin Physiol Pharmacol 2015; 26(1): 13-23. DOI: 10.1515/jbcpp-2013-0150. PMID:: 24756058.</mixed-citation><mixed-citation xml:lang="ru">Prakash A., Kalra J.K., Kumar A. Neuroprotective effect of N-acetyl cysteine against streptozotocin-induced memory dysfunction and oxidative damage in rats. J Basic Clin Physiol Pharmacol 2015; 26(1): 13-23. DOI: 10.1515/jbcpp-2013-0150. PMID:: 24756058.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><mixed-citation>Salkovic-Petrisic M., Knezovic A., Hoyer S. et al. What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research. J Neural Transm 2013; 120: 233–252. DOI: 10.1007/s00702-012-0877-9. PMID: 22886150.</mixed-citation></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Correia S.C., Santos R.X., Santos M.S. et al. Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer’s disease. Curr Alzhei-mer Res 2013; 10: 406–419. PMID: 23061885.</mixed-citation><mixed-citation xml:lang="ru">Correia S.C., Santos R.X., Santos M.S. et al. Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer’s disease. Curr Alzheimer Res 2013; 10: 406–419. PMID: 23061885.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Ishrat T., Hoda M.N., Khan M.B. et al. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alz-heimer’s type (SDAT). Eur Neuropsychopharmacol 2009; 19: 636–647. DOI: 10.1016/j.euroneuro.2009.02.002. PMID: 19329286.</mixed-citation><mixed-citation xml:lang="ru">Ishrat T., Hoda M.N., Khan M.B. et al. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer’s type (SDAT). Eur Neuropsychopharmacol 2009; 19: 636–647. DOI: 10.1016/j.euroneuro.2009.02.002. PMID: 19329286.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><mixed-citation>Paxinos G., Watson Ch. The rat brain in stereotaxic coordinates. 4th edition. Acafemic Press, 1998.</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Goryacheva M.A., Makarova M.N. [Features of the glucose tolerance test in small laboratory rodents (mice and rats)]. Mezhdunarodnyi vestnik veterinarii 2016; 3: 155-159 (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Горячева М.А., Макарова М.Н. Особенности проведения глюкозотолерантного теста у мелких лабораторных грызунов (мыши и крысы). Международный вестник ветеринарии 2016; 3: 155-159.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">. Nazarenko G.I., Kishkun A.A. Klinicheskaya otsenka rezul’tatov labora-tornykh issledovaniy [Clinical evaluation of laboratory results] Moscow: Med-itsina 2000. 544p. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Назаренко Г.И., Кишкун А.А. Клиническая оценка результатов лабораторных исследований. М.: Медицина, 2000. 544 с.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Junod A., Lambert A.E., Stauffacher W. et al. Diabetogenic action of strep-tozotocin: relationship of dose to metabolic response. J Clin Invest 1969; 48: 2129–2139. DOI: 10.1172/JCI106180. PMID: 4241908.</mixed-citation><mixed-citation xml:lang="ru">Junod A., Lambert A.E., Stauffacher W. et al. Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest 1969; 48:2129–2139. DOI: 10.1172/JCI106180. PMID: 4241908.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Lanfray D., Arthaud S., Ouellet J. et al. Gliotransmission and brain glucose sensing: critical role of endozepines. Diabetes 2013; 62: 801–810. DOI: 10.2337/db11-0785. PMID: 23160530.</mixed-citation><mixed-citation xml:lang="ru">Lanfray D., Arthaud S., Ouellet J. et al. Gliotransmission and brain glucose sensing: critical role of endozepines. Diabetes 2013; 62: 801–810. DOI: 10.2337/ db11-0785. PMID: 23160530.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Grünblatt E., Salkovic-Petrisic M., Osmanovic J. et al. Brain insulin sys-tem dysfunction in streptozotocin intracerebroventricularly treated rats gener-ates hyperphosphorylatedtau protein. J Neurochem 2007; 101: 757–770. DOI: 10.1111/j.1471-4159.2006.04368.x. PMID: 17448147.</mixed-citation><mixed-citation xml:lang="ru">Grünblatt E., Salkovic-Petrisic M., Osmanovic J. et al. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylatedtau protein. J Neurochem 2007; 101: 757–770. DOI:10.1111/j.1471-4159.2006.04368.x. PMID: 17448147.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Knezovic А., Loncar A., Homolak J. et al. Rat brain glucose transporter-2, insulin receptor and glial expression are acute targets of intracerebroventricular streptozotocin: risk factors for sporadic Alzheimer’s disease? J Neural Transm2017; 124(6): 695–708. DOI: 10.1007/s00702-017-1727-6. PMID: 28470423.</mixed-citation><mixed-citation xml:lang="ru">Knezovic А., Loncar A., Homolak J. et al. Rat brain glucose transporter-2, insulin receptor and glial expression are acute targets of intracerebroventricular streptozotocin: risk factors for sporadic Alzheimer’s disease? J Neural Transm 2017; 124(6): 695–708. DOI: 10.1007/s00702-017-1727-6. PMID: 28470423.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">de la Monte S.M. Type 3 diabetes is sporadic Alzheimer s disease: Mini-re-view. Eur Neuropsychopharmacol 2014; 24: 1954–1960. DOI: 10.1016/j.euroneu-ro.2014.06.008. PMID: 25088942.</mixed-citation><mixed-citation xml:lang="ru">de la Monte S.M. Type 3 diabetes is sporadic Alzheimer s disease: Mini-review. Eur Neuropsychopharmacol 2014; 24: 1954–1960. DOI: 10.1016/j.euroneuro.2014.06.008. PMID: 25088942.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><mixed-citation>de la Monte S.M., Tong M. Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem Pharmacol 2014; 88: 548–559. DOI: 10.1016/j.bcp.2013.12.012. PMID: 24380887.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Lester-Coll N., Rivera E.J., Soscia S.J. et al. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer’s disease. J Alzheimers Dis 2006; 9: 13–33. DOI: 10.3233/JAD-2006-9102. PMID: 16627931.</mixed-citation></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">de la Monte S.M., Tong M., Lester-Coll N. et al. Therapeutic rescue of neu-rodegeneration in experimental type 3 diabetes: relevance to Alzheimer’s disease. J Alzheimers Dis 2006; 10: 89–109. DOI: 10.3233/JAD-2006-10113. PMID: 16988486.</mixed-citation><mixed-citation xml:lang="ru">de la Monte S.M., Tong M., Lester-Coll N. et al. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer’s disease. J Alzheimers Dis 2006; 10: 89–109. DOI: 10.3233/JAD-2006-10113. PMID:16988486.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">. Iliff J.J., Wang M., Liao Y. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 2012; 4: 147. DOI: 10.1126/scitranslmed.3003748. PMID: 22896675.</mixed-citation><mixed-citation xml:lang="ru">Iliff J.J., Wang M., Liao Y. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 2012; 4: 147. DOI: 10.1126/scitranslmed.3003748. PMID: 22896675.</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><mixed-citation>Blondel O., Portha B. Early appearance of in vivo insulin resistance in adult streptozotocin-injected rats. Diabete Metab 1989; 15: 382–387. PMID: 2697607.</mixed-citation></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Ju C., Yue W., Yang Z. et al. Antidiabetic effect and mechanism of chi-tooligosaccharides. Biol Pharm Bull 2010; 33(9): 1511–1516. DOI: 10.1248/bpb.33.1511. PMID: 20823566.</mixed-citation><mixed-citation xml:lang="ru">Ju C., Yue W., Yang Z. et al. Antidiabetic effect and mechanism of chitooligosaccharides. Biol Pharm Bull 2010; 33(9): 1511–1516. DOI: 10.1248/bpb.33.1511. PMID: 20823566.</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Panchal S.K., Poudyal H., Iyer A. et al. High-carbohydrate, high-fat di-et-induced metabolic syndrome and cardiovascular remodeling in rats. J Car-diovasc Pharmacol 2011; 57(5): 611–624. DOI: 10.1097/FJC.0b013e3181feb90a. PMID: 21572266.</mixed-citation><mixed-citation xml:lang="ru">Panchal S.K., Poudyal H., Iyer A. et al. High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol 2011; 57(5): 611–624. DOI: 10.1097/FJC.0b013e3181feb90a. PMID: 21572266.</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Fine J.M., Forsberg A.C., Stroebel B.M. et al. Intranasal deferoxamine af-fects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer’s disease. J Neurol Sci 2017; 380: 164-171. DOI: 10.1016/j.jns.2017.07.028. PMID: 28870559.</mixed-citation><mixed-citation xml:lang="ru">Fine J.M., Forsberg A.C., Stroebel B.M. et al. Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer’s disease. J Neurol Sci 2017; 380: 164-171. DOI: 10.1016/j. jns.2017.07.028. PMID: 28870559.</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Ayala J.E., Bracy D.P., McGuinness O.P. et al. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 2006; 55: 390–397. DOI: 10.2337/diabetes.55.02.06.db05-0686. PMID: 16443772.</mixed-citation><mixed-citation xml:lang="ru">Ayala J.E., Bracy D.P., McGuinness O.P. et al. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 2006;55: 390–397. DOI: 10.2337/diabetes.55.02.06.db05-0686. PMID: 16443772.</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">Muniyappa R., Lee S., Chen H. et al. Current approaches for assessing in-sulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294: 15–26. DOI: 10.1152/ajpen-do.00645.2007. PMID: 17957034.</mixed-citation><mixed-citation xml:lang="ru">Muniyappa R., Lee S., Chen H. et al. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294: 15–26. DOI: 10.1152/ajpendo. 00645.2007. PMID: 17957034.</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">Butakova S.S., Nozdrachyov A.D. [Effect of calcitonin on the nature of nu-tritional hyperglycemia in rats of different ages and sexes]. Uspekhi gerontologii2010; 23(2): 213-220 (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Бутакова С.С., Ноздрачёв А.Д. Влияние кальцитонина на характер алиментарной гипергликемии у крыс разного возраста и пола Успехи геронтологии 2010; 23(2): 213-220.</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Knezovic A., Osmanovic-Barilar J., Curlin M. et al. Staging of cognitive defi-cits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer’s disease. J Neural Transm 2015; 122(4): 577-592. doi: 10.1007/s00702-015-1394-4 PMID: 25808906.</mixed-citation><mixed-citation xml:lang="ru">Knezovic A., Osmanovic-Barilar J., Curlin M. et al. Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer’s disease. J Neural Transm 2015; 122(4): 577-592. DOI:10.1007/s00702-015-1394-4. PMID: 25808906.</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">Morales R., Duran-Aniotz C., Castilla J. et al. De novo induction of amy-loid-β deposition in vivo. Mol Psychiatry 2012; 17(12): 1347-53. DOI: 10.1038/mp.2011.120. PMID: 21968933</mixed-citation><mixed-citation xml:lang="ru">Morales R., Duran-Aniotz C., Castilla J. et al. De novo induction of amyloid-β deposition in vivo. Mol Psychiatry 2012; 17(12): 1347-1353. DOI: 10.1038/mp.2011.120. PMID: 21968933.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
